Overview
Kidney transplantation is the best available treatment option for patients with end stage renal disease. However, kidney transplantation requires life-long use of immunosuppressive medication. Because of the high cost of these medications we need to carefully evaluate the cost-effectiveness of each drug regimen, especially in low-middle income countries. The objective of this clinical trial is to compare the efficiency and cost of two immunosuppressive protocols after living donor kidney transplantation: (1) antithymocyte globulin, tacrolimus, azathioprine and prednisolone versus (2) basiliximab, tacrolimus, mycophenolate mofetil and prednisolone.
Eligibility
Inclusion Criteria:
- Adult end-stage renal disease patients
- First living donor kidney transplant.
- Moderate immunological risk.
Exclusion Criteria:
- Low immunological risk (HLA mismatches 000/100/010/110 with negative PRA).
- High immunological risk (child to mother or husband to wife transplant, 2 DR
mismatches).
- Known hypersensitivity to any of the study medication.